In short
There are currently 2 ongoing clinical trials investigating treatments for placenta praevia. These studies are exploring ways to prevent preterm birth and reduce blood loss during delivery in women with this condition, using medications such as progesterone and tranexamic acid.
Clinical trial locations
- France
- Netherlands
Study on Progesterone to Prevent Preterm Birth in Pregnant Women with Placenta Previa
This trial is investigating whether progesterone can help prevent preterm birth in women diagnosed with placenta praevia. The condition occurs when the placenta covers the cervix, which can lead to complications during pregnancy and potentially early delivery.
Who can participate: Women who are pregnant with a single baby and have been diagnosed with placenta praevia between 18 and 24 weeks of pregnancy are eligible. Participants should not have any other high-risk factors for preterm birth.
Who cannot participate: Women without placenta praevia, those not at risk of preterm birth, and men are excluded from this study.
What the study involves: The investigational treatment uses progesterone, a naturally occurring hormone that plays an important role in maintaining pregnancy. It is administered through the vagina, starting between 18 and 24 weeks of pregnancy and continuing until delivery or until preterm birth occurs before 37 weeks. The study will monitor how well progesterone works in reducing early births and will check for any side effects in mothers. Researchers will also assess the health of newborns, including birth weight and the need for special care after delivery.
Main goal: The primary focus is to determine whether progesterone can effectively reduce the rate of births occurring before 37 weeks of pregnancy in women with this condition. Regular monitoring throughout pregnancy will assess the duration of pregnancy, newborn health, and maternal side effects.
Study on Tranexamic Acid to Prevent Blood Loss in Women with Placenta Previa Undergoing Cesarean Delivery
This trial is examining whether tranexamic acid can reduce blood loss in women with placenta praevia who are undergoing cesarean delivery. The condition can cause complications during delivery, including excessive bleeding known as postpartum hemorrhage.
Who can participate: Women who are 18 years or older with placenta praevia confirmed by recent ultrasound, who are having a planned cesarean delivery at 32 weeks of pregnancy or later. Participants must have access to a health security system and must provide signed informed consent.
Who cannot participate: Women who do not have placenta praevia, those not undergoing cesarean delivery, and men are excluded from this study.
What the study involves: The investigational drug is tranexamic acid, a medication that helps prevent excessive bleeding by supporting blood clotting. A low dose of 1 gram is given through an injection within 3 minutes after the baby is delivered, in addition to standard medications that help the uterus contract. The study compares tranexamic acid to a placebo to see if it reduces the need for blood transfusion before hospital discharge. Participants will be monitored for blood loss, potential side effects such as nausea or dizziness, and serious complications like blood clots. Additional care may include iron supplementation if needed.
Main goal: The primary aim is to determine whether administering tranexamic acid shortly after delivery can reduce the need for blood transfusion in women with this condition. The study also assesses maternal recovery, satisfaction with delivery experience, and psychological well-being through questionnaires at various time points up to 12 weeks after delivery.
Summary
Currently, there are two clinical trials addressing different aspects of care for women with placenta praevia. One trial in the Netherlands focuses on preventing preterm birth using progesterone during pregnancy, while another in France aims to reduce blood loss during cesarean delivery using tranexamic acid. These studies reflect an international effort to improve outcomes for mothers and babies affected by this condition. Each trial investigates a distinct treatment approach, targeting either pregnancy maintenance or delivery complications. Both studies emphasize careful monitoring of maternal and infant health throughout participation.
